Background: Accumulating case reports have described tendon rupture in men who use anabolic-androgenic steroids (AAS). However, no controlled study has assessed the history of tendon rupture in a large cohort of AAS users and comparison nonusers.
Abuse of anabolic-androgenic steroids (AAS), among both competitive athletes and recreational bodybuilders, has grown into a major substance-abuse problem in the United States and most other Western countries. 45 Before about 1980, AAS use was largely confined to elite athletes, but over the past 3 decades the use of these drugs has become widespread in the general population. 18 A recent study calculated that between 2.9 and 4.0 million American men have used AAS at some time in their lives and that perhaps 1 million of these men have developed AAS dependence, with chronic AAS use often persisting despite adverse medical and psychiatric effects. 44 Among the various adverse effects of long-term AAS use is an apparently elevated risk of tendon rupture, as suggested by accumulating case reports over the past 30 years. In the world literature to date, we have found 14 reports describing tendon rupture in acknowledged AAS users | | and 4 additional reports describing individuals in whom AAS use was not acknowledged but appears likely. 1, 3, 4, 48 As shown in the Appendix (available online at http://ajsm .sagepub.com/supplemental), all patients were male, ranging in age from their 20s to their 40s and typically reporting long-term use of AAS for bodybuilding or other athletic activities. Although some men ruptured a tendon while weightlifting, many of the cases occurred as a result of a fall, sports injury, or simply lifting an object. Many of the men ruptured 2 or more tendons, with some cases of bilateral simultaneous ruptures and other cases in which different tendons were ruptured at different times over the course of months or years of AAS use. Collectively, these observations would seem to suggest that AAS use increases the risk for tendon rupture, and this impression has been widely shared in various reviews examining the adverse effects of AAS use. 26, 29, 40, 45 However, we are not aware of any quantitative studies showing that tendon rupture is indeed more common in AAS users than in otherwise similar men with a comparable history of regular weightlifting. Also of note, we have been unable to find any reports of tendon rupture in AAS users before 1980. Thus one might argue that the association of AAS use and tendon rupture is coincidental and that with the massively increased numbers of AAS users after 1980, one might see an overlap of AAS use and tendon rupture simply by chance. Perhaps in favor of this possibility, it should be noted that some of the putative cases of AAS-associated tendon rupture occurred in men who had also been treated with corticosteroids, 49, 51 and these drugs, rather than AAS, may have been responsible for tendon injuries. 25 Arguing against this possibility, however, is the observation that many of the reported AAS-associated cases involved rupture of the triceps brachii and biceps brachii tendons. These are relatively rare injuries, and thus the accumulation of AAS-associated cases is hard to ascribe to coincidence.
To provide more quantitative data on the association of AAS use with tendon rupture, we assessed the risk of tendon rupture in 88 male long-term AAS users and 54 comparison men reporting a similar degree of weightlifting experience but no history of AAS use, all recruited in the course of 2 ongoing studies.
METHODS

Design of the Parent Studies
Participants for the present study were drawn from 2 current studies whose primary aims were to evaluate cardiac and other medical conditions in AAS users. In both studies, we recruited men aged 35 to 55 years who were experienced bodybuilders and who reported either (1) at least 2 years of cumulative lifetime AAS use or (2) no lifetime AAS use.
Although neither of the 2 studies was focused exclusively on orthopaedic injuries, we obtained a medical history with attention to musculoskeletal injuries in all participants, since such injuries are common among weightlifters. Our studies were focused on men because AAS use is rare in women, 19 and long-term AAS use is extremely rare in women, 44 despite some misconceptions to the contrary. 17, 45 We chose a 2-year threshold for cumulative lifetime AAS use, on the basis of findings of prior studies, 20, 42 to secure men with substantial AAS exposure and consequently greater risk for potential long-term AAS effects.
We recruited study participants by advertising in gymnasiums in the Boston, Massachusetts, area, using recruitment techniques that we have described in detail previously. 20, 42 Briefly, our advertisement requested men who could ''bench-press 275 pounds for at least 1 repetition, currently or in the past, for a psychiatric and medical evaluation.'' As we have explained in our previous studies, 20, 42 the 275-pound threshold was simply a method to secure an unselected group of experienced weightlifters. Notably, we screened advertisement respondents by telephone and invited them to participate in the studies without asking about their history of AAS use or revealing our specific interest in AAS. By this method, we sought to minimize selection bias that might arise if participants were informed in advance about the exposure variable of interest.
Individuals qualifying on telephone screening for the studies were then scheduled for a screening interview where we administered (1) demographic questions; (2) questions about lifetime weightlifting and exercise history, including information about interruptions of regular exercise attributable to injury; (3) determination of height, weight, and body fat-the latter based on 6 skin caliper measurements using the equations of Jackson and Pollock 16 ; (4) medical history, including overall health, prior hospitalizations, and current prescription medications; (5) psychiatric and substance-abuse history, using the Structured Clinical Interview for DSM-IV (SCID) 10 ; and (6) history of use of AAS and other performance-enhancing drugs, if any. In men acknowledging use of AAS, we elicited detailed information about the particular drugs used, together with an estimate of the individual's total lifetime dose of AAS in milligrams, calculated as milligrams of testosterone equivalent as described previously, 20, 42 and the total cumulative duration of time that the individual was actually using steroids during the course of his life. We also collected urine and hair samples from all participants. We tested urine samples for AAS, for the performance-enhancing drug clenbuterol, and for opiates, amphetamines, cannabis, cocaine, and phencyclidine (Anti-Doping Research, Los Angeles, California), using methods previously described. 5, 6 We tested hair samples for opiates, cannabis, phencyclidine, amphetamines, and cocaine (Psychemedics Corp) from the last 90 days. We excluded participants who displayed urine or hair results inconsistent with their self-reports of AAS or other substance use. We also calculated participants' fat-free mass index (FFMI), a measure of muscularity that we have previously presented, 23 on the basis of our measurements of height, weight, and body fat. We excluded participants who denied having used AAS but who showed an FFMI greater than 25.5 kg/m 2 while showing body fat of less than 10%, as we have previously shown that an FFMI beyond this threshold in a lean individual likely reflects surreptitious AAS use. 23 After the screening evaluation, participants were referred for a medical evaluation with a particular focus on cardiovascular function. In the course of these latter evaluations, participants received a second review of medical history from a study physician. We have reported preliminary findings from the first study 46, 55 ; findings from the second study are still being analyzed.
The above procedures in both studies were approved by the institutional review boards of our institutions, and all participants provided written informed consent before study procedures were undertaken.
Participants and Methods for the Present Study
We evaluated a total of 88 long-term AAS users and 54 non-AAS-using weightlifters in the course of the 2 parent studies between February 2011 and November 2014. The larger size of the AAS group was by design, as we wanted greater statistical power to examine subgroups within the AAS users. Over this interval, we noted a remarkable number of participants who reported a history of 1 or more tendon ruptures. Accordingly, we reviewed each participant's medical history, using both the medical history information obtained at screening and information from the second medical history obtained at the subsequent evaluation in each study. We found that among the 142 men, 23 had reported at least 1 definite or possible tendon rupture. We recorded each participant's age and type of activity at the time of the injury, together with his total cumulative lifetime use of AAS (if any) as of that date. If applicable, we also recorded whether participants were currently using AAS at the moment of injury and the drugs and doses that they were taking. We also recorded any other drugs, including prescription medications, over-thecounter medications, illicit drugs, and alcohol, that the participant reported using at the time. Finally, we recorded whether participants had experienced any prodromal symptoms, such as pain in the region of the tendon rupture, before the injury itself. We also successfully recontacted 22 of the 23 identified participants to request that they sign a release granting us permission to obtain copies of the surgical notes or other medical records describing the tendon repair.
Statistical Analysis
For comparisons between AAS users and nonusers on demographic variables, we used linear regression for continuous variables and the Fisher exact test for categorical variables. To examine the association between AAS use and tendon rupture, we used a cross-sectional cohort design. In a previous methodological paper, we formally presented the properties of this design, including the conditions required for its validity. 13 Briefly, the crosssectional cohort design samples a source population cross-sectionally and then measures the association between exposures (in this case AAS use) and outcomes (in this case tendon rupture) assessed retrospectively.
As the primary measure of risk for tendon rupture, we estimated the hazard ratio for first tendon rupture, adjusted for self-defined race (modeled as white vs nonwhite) in AAS users compared with nonusers by a Cox proportional hazards model, with AAS as a time-varying exposure (ie, unexposed until onset of AAS use, and exposed after onset of AAS use). Thus, the hazard ratio represents an estimate of the probability that a first tendon rupture will occur at any given age among individuals who have been exposed to AAS, divided by the probability that a first tendon rupture will occur at that same age among individuals who have not been exposed to AAS. We adjusted for race on the basis of evidence for racial differences in vulnerability to tendon rupture. 41 As a secondary measure of risk for tendon rupture, we estimated the mean total number of tendon ruptures in AAS users versus nonusers, using linear regression, adjusted for race.
Alpha was set at .05, 2-tailed. The analyses were performed with Stata 12.0 software (Stata Corp).
RESULTS
The 88 long-term AAS users and 54 nonusing weightlifters were closely matched in age (mean 6 SD, 42.9 6 5.2 vs 43.2 6 6.1 years; P = .73), as would be expected since they were chosen to be age 35 to 55, as described above. All of the men lifted weights for the purpose of bodybuilding, although only a minority of them had participated in actual bodybuilding competitions. None of the men had competed in powerlifting or in Olympic weightlifting. The 2 groups of men were similar in their reported lifetime years of weightlifting (mean 6 SD, 20.8 6 6.6 years [AAS users], 20.0 6 9.5 years [nonusers]; P = .61), but they differed somewhat in racial distribution (AAS users: 82 white, 6 African American; nonusers: 41 white, 12 African American, 1 Asian; P = .005 for white vs nonwhite). Of the 23 men with definite or possible tendon rupture, 1 was excluded after further review because his surgical records showed an intact biceps tendon; his injury was a torn glenoid labrum. (Specifically, the surgical note stated, ''the biceps tendon appeared completely within normal limits. The attachment of the biceps itself was carefully probed and noted to be normal; however at the 1 o'clock position, just anterior to the biceps insertion, there was detachment which appeared to be traumatic in nature of the labrum. . . . This was repaired. . . . '') Of the remaining 22 men with definite tendon ruptures (Table 1) , 19 were AAS users, representing 22% of the total AAS-using group of 88, and only 3 were nonusing weightlifters, representing 6% of the 54 men in that group. None of the AAS users had ruptured a tendon before first using AAS.
The time-to-event distributions (survival curves) for first tendon rupture in the AAS users and nonusers are presented in Figure 1 . The hazard ratio in the AAS users versus the nonusers was 9.0 (95% CI, 2.5-32.3; P \ .001). The percentage of men with lower-body tendon ruptures was 7% (6 cases) in the AAS group versus 6% (3 cases) in the nonuser group, with a nonsignificant hazard ratio for first lower-body tendon rupture of 3.1 (95% CI, 0.7-13.8; P = .13). By contrast, upper-body tendon ruptures were reported by 17% of the AAS users (15 individuals) versus 0% of the nonusers. Since there were zero cases among the nonusers, we could not estimate the hazard ratio for this comparison. Therefore, we instead estimated the risk difference, using an approach suggested by Spiegelman and Hertzmark 50 that employed a generalized linear regression model using the binomial distribution and the identity link function. This approach yielded a risk difference of 0.17 (95% CI, 0.09-0.25; P \ .001).
As shown in Table 1 , several men had ruptured 2 tendons and 1 had ruptured 4 tendons over the course of a lifetime. In all cases, these ruptures occurred on separate occasions rather than simultaneously. The total number of tendon ruptures was 27 (19 upper body and 8 lower body) in the AAS group and 5 (all lower body) in the nonuser group. The estimated adjusted mean difference between groups in number of lifetime tendon ruptures per person was 0.27 (95% CI, 0.06-0.48; P = .011); for upper-body ruptures alone, the difference was 0.21 (95% CI, 0.07-0.35; P = .004), and for lower-body ruptures alone it was 0.06 (-0.07 to 0.18; P = .38). Among the 32 separate tendon ruptures that occurred in the 2 groups collectively, only 6 occurred during weightlifting (representing 19% of the 31 cases for which history was obtained). Interestingly, several of these men recalled that they were lifting a light weight, just after a workout with much heavier weights, at the moment that the rupture occurred. A majority of the ruptures occurred during sports activities, with the remainder of cases attributed to falls or to moving or carrying heavy objects. Of the 14 biceps ruptures, 8 occurred at the distal end of the biceps (at the elbow), and 6 involved the long head of the biceps (at the shoulder). Of the 2 triceps ruptures, both occurred distally. Of the 31 ruptures for which history was obtained, 8 (26%) were preceded by pain in the vicinity of the site of the rupture, whereas the remainder occurred without warning. At the time of the rupture, 2 of the men were intoxicated with alcohol and 2 were using oxycodone (illicit in 1 case and medically prescribed in the other). One man had recently received corticosteroid injections for back pain, raising the possibility that in his case, corticosteroid exposure-a known risk factor for tendon rupture 22, 25, 53 -had contributed to his vulnerability to tendon rupture.
Almost all of the AAS users were taking a course of AAS at the time of the injury, usually at markedly supraphysiologic doses. As shown in the table, the users reported typical weekly doses between 210 and 2500 mg of total AAS per week, representing 3.5 to 40 times the normal male endogenous production of about 60 mg of testosterone per week. At the time of their tendon ruptures, many users had accumulated well over a decade of cumulative lifetime steroid use (ie, total weeks during which they were actually using AAS), for a total lifetime dose of hundreds of thousands of milligrams.
Virtually all cases of tendon rupture were treated surgically, and all subjects reported complete or nearly complete return of function after completing rehabilitation from the surgical repair.
DISCUSSION
Over the past 2 decades, various case reports and small case series have described tendon rupture in men using AAS, suggesting that use of these drugs may render individuals particularly prone to this type of injury. However, no study, to our knowledge, has systematically assessed history of tendon rupture in a large sample of AAS users and comparison weightlifters without AAS exposure. In the present study, we used a cross-sectional cohort study design to examine the risk of tendon rupture in 88 weightlifters who used AAS versus 54 who did not. The risk for first tendon rupture, as assessed by the hazard ratio, was 9.0 times greater in the AAS users compared with the nonusers. In addition, the mean total number of lifetime tendon ruptures was markedly higher among the AAS users. Interestingly, the elevation in risk for lower-extremity tendon ruptures was much less than that for upper-extremity ruptures.
These findings have several implications for public health and injury prevention. First, they suggest that the risk for tendon rupture, particularly upper-body tendon rupture, is much greater among AAS users than among otherwise similar men with comparable years of exposure to weightlifting. Thus, our findings strongly support the impression that AAS use is indeed a risk factor for tendon rupture. By identifying those at risk for AAS use and offering counseling on the risk of tendon rupture as well as other adverse effects of AAS use, clinicians might reduce the use of AAS and subsequent tendon rupture among high-risk populations. 29, 45 The causes of AAS-associated tendon rupture are still incompletely understood. Two alternative (and not mutually exclusive) hypotheses should be considered. One possibility is that AAS use has little or no deleterious effect on tendons themselves but merely causes massive hypertrophy of muscles without causing any corresponding strengthening of the associated tendons. Thus, the muscle may simply become too strong for its tendon, increasing the possibility of rupture in response to a sudden stress. Alternatively, it is possible that high doses of AAS, perhaps in conjunction with intense muscular exercise, may damage the structure of the tendons themselves, making them more vulnerable to rupture even in the absence of excessive stress. Evidence favoring the latter hypothesis comes from various animal studies, which have typically found that AAS exposure, usually in conjunction with exercise, led to collagen dysplasia, causing tendons to become stiffer and less flexible, with an increased crimp angle and earlier liability to failure. 14, 21, [30] [31] [32] [34] [35] [36] [37] [38] [39] 52 However, 1 human study using electron microscopy found no evidence of collagen fibril ultrastructural abnormalities in the ruptured tendons of 2 AAS users compared with 2 non-AASusing controls. 9 Another recent study found no significant difference in maximal strain and toe limit strain in the patellar tendons of 8 long-term AAS users compared with 8 experienced weightlifters reporting no AAS use, also arguing against the hypothesis of changes in collagen crimp pattern associated with AAS use. 47 Thus, the evidence for a direct toxic effect of AAS on human tendons remains somewhat inconclusive.
Although our study provides no direct evidence on the above issues, it is notable that we found a markedly increased risk of upper-body tendon ruptures in AAS users versus nonusing weightlifters, whereas the risk of lowerbody tendon ruptures was only modestly and nonsignificantly increased among AAS users. If indeed AAS use causes damage to human tendon architecture, one might predict that our AAS users, with histories of very extensive exposure to very high doses of AAS, would show a uniformly elevated prevalence of all types of tendon rupture throughout the body rather than primarily an elevated risk of upper-body tendon ruptures. Therefore, our findings might be taken to weigh, at least to some degree, against a hypothesis of direct tendon damage and might weigh more in favor of the simple theory that hypertrophied muscles can more easily break their tendons. In favor of the latter possibility, it is notable that AAS users are particularly prone to increased upper-body musculature, leading to massively hypertrophied pectoralis, biceps brachii, and triceps brachii muscles, while often showing less of an effect on lower-body musculature. 43 Thus, it is conceivable that muscle hypertrophy alone might account for our findings without postulating an additional mechanism of AAS-induced tendon damage.
Our findings are subject to several methodological limitations. First, because we deliberately selected men aged 35 to 55 years reporting at least 2 years of cumulative AAS exposure for our parent studies, our sample of men is not representative of the entire population of American AAS users. In particular, younger users, and those reporting briefer exposure to AAS, might well be less likely to have experienced a tendon rupture.
Second, we cannot exclude the possibility of unmeasured confounding variables, in that some other aspect of AAS users' lifestyle, such as concomitant use of other non-AAS drugs, might have contributed increased vulnerability to tendon rupture.
Third, our parent studies were not initially designed to elicit a detailed and exhaustive orthopaedic history from study participants. Thus, it is possible that a study participant might have experienced a tendon rupture but simply failed to mention this on his medical history, because he was not explicitly and systematically queried about orthopaedic injuries. If such an omission occurred, however, it would have caused an underestimate of the risk of tendon rupture in this population, yielding overly conservative findings.
Fourth, our data were collected retrospectively, with some participants describing injuries that had occurred years earlier. Although we obtained surgical records to validate these injuries in most cases, our findings regarding details such as the circumstances of injury, concomitant drug use, and AAS use at the time of injury were limited by the accuracy of participants' retrospective reporting.
Fifth, 2 forms of selection bias may have influenced our estimates of the hazard ratios for tendon rupture. One is that our selection of available AAS users and nonusers might not have reflected the characteristics of long-term AAS users or of nonusing weightlifters in the general population with respect to risk for tendon rupture. However, this form of selection bias seems unlikely to have greatly influenced the findings, since participants were recruited without being informed of the specific exposure and outcome variables of interest (AAS use and tendon rupture), and it seems unlikely that participants would have chosen to enroll or not enroll in the study on the basis of these variables in any event. The other potential source of selection bias is the possibility of nondifferential exiting from the underlying cohort (ie, the theoretical cohort of individuals entering the source population during the period of time under retrospective observation), as explained in detail in our prior methodological publication presenting the cross-sectional cohort design. 13 However, this phenomenon seems unlikely in the present study, because even if the experience of a prior tendon rupture would influence a potential participant's availability to enroll in our study, there is little reason to believe that such an experience would have a differential influence in AAS users compared with nonusers.
Acknowledging these limitations, we have found persuasive evidence that the risk of tendon rupture is strikingly higher among AAS users than among equally experienced weightlifters who have not used these drugs. Perhaps most notably, AAS users frequently reported a history of upper-body tendon rupture, but we found no cases of upper-body tendon rupture among 54 otherwise similar nonusing weightlifters. These findings would suggest that if a muscular man presents with a ruptured tendon, perhaps especially an upper-body tendon, the clinician should strongly suspect AAS use as a contributing factor. Given the high prevalence of AAS use and dependence in the United States and other Western countries, it appears that AAS-associated tendon rupture represents a significant public health problem, creating substantial costs in medical care, lost productivity, and reduced quality of life.
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